352 related articles for article (PubMed ID: 12692835)
1. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Meijer CJ
J Pathol; 2003 May; 200(1):4-15. PubMed ID: 12692835
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
4. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
[TBL] [Abstract][Full Text] [Related]
5. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
6. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative.
Kadin ME; Pinkus JL; Pinkus GS; Duran IH; Fuller CE; Onciu M; Kawaguchi H; Morris SW
Am J Surg Pathol; 2008 Sep; 32(9):1421-6. PubMed ID: 18670345
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic large cell lymphoma: an unusual presentation in a 7-year-old girl.
Ju E; Adigun C; Dunphy C; Gold S; Morrell DS
Pediatr Dermatol; 2012; 29(4):498-503. PubMed ID: 21967522
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ
Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911
[TBL] [Abstract][Full Text] [Related]
9. Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration.
Marschalkó M; Eros N; Holló P; Hársing J; Bottlik G; Bátai A; Csukly Z; Masszi T; Szentirmai Z; Fodor J; Kárpáti S; Matolcsy A; Csomor J
Am J Dermatopathol; 2010 Oct; 32(7):708-12. PubMed ID: 20644462
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
Hematol Oncol; 2009 Dec; 27(4):161-70. PubMed ID: 19358142
[TBL] [Abstract][Full Text] [Related]
11. Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review.
Balachandran I; Walker JW; Broman J
Diagn Cytopathol; 2010 Mar; 38(3):213-6. PubMed ID: 19774614
[TBL] [Abstract][Full Text] [Related]
12. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
[TBL] [Abstract][Full Text] [Related]
13. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
Hum Pathol; 2006 Jul; 37(7):874-82. PubMed ID: 16784988
[TBL] [Abstract][Full Text] [Related]
15. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation.
Kinney MC; Kadin ME
Am J Clin Pathol; 1999 Jan; 111(1 Suppl 1):S56-67. PubMed ID: 9894470
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
17. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
Herbst H; Sander C; Tronnier M; Kutzner H; Hügel H; Kaudewitz P
Br J Dermatol; 1997 Nov; 137(5):680-6. PubMed ID: 9415224
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
19. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis.
Gorczyca W; Tsang P; Liu Z; Wu CD; Dong HY; Goldstein M; Cohen P; Gangi M; Weisberger J
Int J Oncol; 2003 Feb; 22(2):319-24. PubMed ID: 12527929
[TBL] [Abstract][Full Text] [Related]
20. The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.
Kapur S; Tiemann M; Menke MA; Schubert C; Parwaresch R
Indian J Med Res; 2005 Jan; 121(1):46-54. PubMed ID: 15713979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
